COA ↓

Product

COA Doc

SYN-2623

99.3% Purity SYN-2623 Research Grade HPLC Verified

NAD+

Nicotinamide Adenine Dinucleotide · Research Grade

Select Strength — 100mg

$70.00

C₂₁H₂₇N₇O₁₄P₂ MW: 663.43 g/mol CAS: 53-84-9

Available on Backorder

Backordered — orders ship within 5–10 business days in the sequence received.

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch

HPLC Purity

Lot Number SYN-2623-NAD

Test Date

Labeled 99.3%

Actual 99.3%

HPLC Purity

Lot Number SYN-2522-NAD

Test Date

Labeled 99.3%

Actual 99.6%

Research Data

KEY FINDINGS

🧬

500+

Enzymatic Reactions Driven

NAD+ is required cofactor for over 500 enzymatic reactions in all living cells

🔬

50%

NAD+ Decline Between 40–60

Plasma NAD+ levels fall 50% between ages 40 and 60 — Zhu XH et al.

✅

99.3%

HPLC-Verified Purity

Current batch SYN-2623, third-party accredited lab

❄️

36mo

Lyophilised Shelf Life

At −20°C sealed under inert atmosphere — extended stability

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

⚡ Age-Related Decline

50% NAD+ Decline Between 40–60 — PNAS 2015

Zhu et al. used non-invasive 31P MRS to measure brain NAD+ in living subjects, confirming age-dependent NAD+ decline and demonstrating that NAD+ repletion restored mitochondrial function. This foundational data established the rationale for NAD+ supplementation in longevity research.

🔬 50% NAD+ decline by age 60 — directly impairing mitochondrial function, sirtuin activity, and PARP DNA repair capacity.

PMID 26438842 — PNAS

50 %

NAD+ Declines 50% Between Ages 40 and 60

NAD+ is the master coenzyme driving mitochondrial ATP production, DNA repair via PARP activation, sirtuin-mediated longevity signalling, and cellular redox balance. Plasma NAD+ levels decline approximately 50% between ages 40 and 60 — directly impairing all downstream pathways.

NAD+ Plasma Levels by Age — Human Clinical Data

NAD+ at age 20–30 100%

NAD+ at age 40–50 70%

NAD+ at age 60–70 50%

Source: Zhu XH et al., PNAS, 2015

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2623-NAD

Specification	Value
CAS Number	53-84-9
Molecular Formula	C₂₁H₂₇N₇O₁₄P₂
Molecular Weight	663.43 g/mol
Purity (HPLC)	99.3%
Appearance	White lyophilised powder
Solubility	Soluble in water (10 mg/mL)
Storage	−20°C long-term / 2–8°C short-term
Shelf Life	36 months from production date
Research Grade	Yes — For In Vitro Use Only

50 %

NAD+ Plasma Level Decline Between Ages 40 and 60

Age 20–30 100%

Age 60–70 50%

Comparative Activity Profile

NAD+ (Direct) NMN (Precursor)

Observed Adverse Indicators

12%

Flushing (IV administration)

low

Transient GI discomfort

low

Mild headache

low

Serious adverse events reported

low

⚠️ Theoretical Concern

Stability & Research Handling Notes

NAD+ is intrinsically safe as an endogenous molecule. The primary research consideration is its extreme sensitivity to oxidation and light degradation after reconstitution.

Endogenous coenzyme — present in all living cells, no xenobiotic toxicity profile
IV NAD+ used clinically in addiction medicine for decades without serious adverse events
Oxidation-sensitive post-reconstitution — store in amber vials at 4°C, use within 14 days
For in vitro laboratory research use only — not for human or veterinary administration

NAD+

BATCH VERIFICATION

KEY FINDINGS

IN VITRO RESEARCH OVERVIEW

50% NAD+ Decline Between 40–60 — PNAS 2015

PURITY VERIFICATION

TRIAL RESULTS

SAFETY PROFILE

Stability & Research Handling Notes

FREQUENTLY ASKED QUESTIONS

RESEARCH CITATIONS